SCHEMBL18574185

SCHEMBL18574185

CCc1cncc(-c2ccccc2Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 5/20 0.43
▸ GAA P10253 1/20 0.43
▸ IDO1 P14902 1/20 0.42
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ TLR8 Q9NR97 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ PIM1 P11309 1/20 0.38
▸ PIM3 Q86V86 1/20 0.38
▸ PIM2 Q9P1W9 1/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CRHR1 P34998 1/20 0.37
▸ POLB P06746 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ ABL1 P00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17034486 0.79 L3MBTL1 (0.48) L3MBTL1GAAIDO1HSP90AA1HSP90AB1
SCHEMBL18573250 0.77 IDO1 (0.46) L3MBTL1GAAIDO1HSP90AA1HSP90AB1
SCHEMBL13515213 0.75 CYP11B2 (0.43) L3MBTL1GAAALDH1A1NPC1RAB9A
SCHEMBL15060604 0.75 CYP1A2 (0.45) L3MBTL1GAAIDO1HSP90AA1HSP90AB1
SCHEMBL3362503 0.74 HSP90AA1 (0.50) L3MBTL1IDO1HSP90AA1HSP90AB1ALDH1A1
SCHEMBL18762205 0.73 TAAR1 (0.40) L3MBTL1IDO1ALDH1A1SMN1; SMN2POLB
SCHEMBL20330306 0.73 IDO1 (0.42) L3MBTL1IDO1HSP90AA1HSP90AB1ALDH1A1
SCHEMBL17034442 0.70 ABL1 (0.42) L3MBTL1GAAHSP90AA1HSP90AB1ALDH1A1
SCHEMBL830961 0.69 NOS3 (0.36) —
SCHEMBL24993568 0.68 PRKDC (0.47) GAAALDH1A1SMN1; SMN2KMT2AHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170066783-A1 Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-03-09 — — US disclosed
US-20170057993-A1 Ether Compounds for Treatment of Medical Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066783-A1 Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders CFD, F12, F3 L3MBTL1 4258/4885GAA 2150/4885IDO1 2501/4885
US-20170057993-A1 Ether Compounds for Treatment of Medical Disorders CFD, TFPI, F12 L3MBTL1 3327/4885GAA 3664/4885IDO1 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback